NO307890B1 - Polyoksypropylen/polyoksyetylen-kopolymerblanding, fremgangsmÕte for fremstilling derav samt medikament omfattende en kopolymerblanding - Google Patents

Polyoksypropylen/polyoksyetylen-kopolymerblanding, fremgangsmÕte for fremstilling derav samt medikament omfattende en kopolymerblanding

Info

Publication number
NO307890B1
NO307890B1 NO933337A NO933337A NO307890B1 NO 307890 B1 NO307890 B1 NO 307890B1 NO 933337 A NO933337 A NO 933337A NO 933337 A NO933337 A NO 933337A NO 307890 B1 NO307890 B1 NO 307890B1
Authority
NO
Norway
Prior art keywords
polyoxypropylene
copolymer blend
polyoxyethylene
preparations
medicament
Prior art date
Application number
NO933337A
Other languages
English (en)
Other versions
NO933337D0 (no
NO933337L (no
Inventor
R Martin Emanuele
Robert L Hunter
Paula H Culbreth
Original Assignee
Cytrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27100911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO307890(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytrx Corp filed Critical Cytrx Corp
Publication of NO933337D0 publication Critical patent/NO933337D0/no
Publication of NO933337L publication Critical patent/NO933337L/no
Publication of NO307890B1 publication Critical patent/NO307890B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/04—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers only
    • C08G65/06—Cyclic ethers having no atoms other than carbon and hydrogen outside the ring
    • C08G65/08—Saturated oxiranes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
    • C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2618—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen
    • C08G65/2621—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen containing amine groups
    • C08G65/2624—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen containing amine groups containing aliphatic amine groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/30—Post-polymerisation treatment, e.g. recovery, purification, drying
NO933337A 1991-03-19 1993-09-17 Polyoksypropylen/polyoksyetylen-kopolymerblanding, fremgangsmÕte for fremstilling derav samt medikament omfattende en kopolymerblanding NO307890B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67328991A 1991-03-19 1991-03-19
US84787492A 1992-03-13 1992-03-13
PCT/US1992/002254 WO1992016484A1 (en) 1991-03-19 1992-03-18 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity

Publications (3)

Publication Number Publication Date
NO933337D0 NO933337D0 (no) 1993-09-17
NO933337L NO933337L (no) 1993-11-17
NO307890B1 true NO307890B1 (no) 2000-06-13

Family

ID=27100911

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933337A NO307890B1 (no) 1991-03-19 1993-09-17 Polyoksypropylen/polyoksyetylen-kopolymerblanding, fremgangsmÕte for fremstilling derav samt medikament omfattende en kopolymerblanding

Country Status (19)

Country Link
US (7) US5523492A (no)
EP (1) EP0576612B1 (no)
JP (1) JP2647556B2 (no)
KR (1) KR100224539B1 (no)
CN (1) CN1069741A (no)
AT (1) ATE187154T1 (no)
AU (1) AU662146B2 (no)
CA (1) CA2106474C (no)
CZ (1) CZ194693A3 (no)
DE (1) DE69230372T2 (no)
DK (1) DK0576612T3 (no)
ES (1) ES2140408T3 (no)
GR (1) GR3032726T3 (no)
HU (1) HUT67762A (no)
IE (1) IE920860A1 (no)
IL (1) IL101305A (no)
NO (1) NO307890B1 (no)
SK (1) SK100893A3 (no)
WO (1) WO1992016484A1 (no)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
USRE38558E1 (en) 1991-03-19 2004-07-20 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
KR100224539B1 (ko) * 1991-03-19 1999-10-15 잭 제이 루체스 개선된 생물학적 활성을 가진 폴리옥시프로필렌/폴리옥시에틸렌 공중합체 조성물
US7202225B1 (en) 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
CA2155005C (en) * 1993-02-02 1999-04-06 Weldon Courtney Mcgregor Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
ES2189808T3 (es) * 1993-10-15 2003-07-16 Cytrx Corp Composiciones de aporte terapeutico y metodos de uso de las mismas.
US5932544A (en) 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
EP1181937A3 (en) * 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
WO1998013069A2 (en) 1996-09-09 1998-04-02 Supratek Pharma, Inc. Fluorinated copolymeric pharmaceutical adjuncts
US6312685B1 (en) 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
US6942859B2 (en) 1998-03-13 2005-09-13 University Of Southern California Red blood cells covalently bound with polymers
WO2000021543A1 (en) * 1998-10-09 2000-04-20 Cytrx Corporation Method and composition for treating ischemia and sickle cell anemia
AU779887B2 (en) * 1999-06-08 2005-02-17 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
CA2411167A1 (en) * 2000-06-23 2002-01-03 Merck & Co., Inc. Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use
US6761824B2 (en) 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
US20040266983A1 (en) * 2000-08-17 2004-12-30 Reeve Lorraine E Purified polyoxyalkylene block copolymers
ATE503463T1 (de) * 2000-10-20 2011-04-15 Vical Inc Gen-abgabeformulierungen zur behandlung ischämischer zustände
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
US6492881B2 (en) * 2001-01-31 2002-12-10 Compaq Information Technologies Group, L.P. Single to differential logic level interface for computer systems
WO2002092107A1 (en) * 2001-04-24 2002-11-21 Purdue Research Foundation Method and compositions for treating mammalian nerve tissue injuries
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
NZ538255A (en) * 2002-07-29 2006-11-30 Transform Pharmaceuticals Inc Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
JP5390059B2 (ja) * 2002-12-23 2014-01-15 バイカル インコーポレイテッド 無菌ポリヌクレオチド系薬剤の製造方法
JP4917263B2 (ja) * 2002-12-23 2012-04-18 バイカル インコーポレイテッド 核酸／ブロックコポリマー／陽イオン性界面活性剤複合体を凍結乾燥する方法
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
AU2004224439B2 (en) * 2003-03-24 2010-07-15 Genzyme Corporation Temporary embolization using inverse thermosensitive polymers
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
BRPI0413771A (pt) * 2003-09-05 2006-10-31 Ivy Animal Health Inc copolìmeros de polioxipropileno/polioietileno purificados e método de preparação dos mesmos
WO2005037062A2 (en) 2003-10-14 2005-04-28 Pluromed, Inc. Confinement of kidney-stone fragments during lithotripsy
WO2005046438A2 (en) 2003-11-06 2005-05-26 Pluromed, Inc. Internal clamp for surgical procedures
JP4521547B2 (ja) * 2004-04-15 2010-08-11 株式会社サンメディカル技術研究所 血液ポンプの流量推定装置
US20060134221A1 (en) * 2004-12-03 2006-06-22 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
ES2380047T3 (es) * 2005-02-25 2012-05-08 The Regents Of The University Of Michigan Composiciones y procedimientos para el tratamiento y prevención de la miocardiopatía y la enfermedad cardiaca
EP2279756A2 (en) 2005-04-05 2011-02-02 Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A. Method for shielding functional sites or epitopes on proteins
ES2529130T3 (es) 2005-05-02 2015-02-17 Genzyme Corporation Terapia no litotrípsica de cálculos renales
US8815557B2 (en) * 2005-07-08 2014-08-26 University Of Chicago Compositions and methods for refolding of denatured proteins
US20080031847A1 (en) * 2005-12-22 2008-02-07 Pluromed, Inc. Methods and kits for treating lacerations and puncture wounds using inverse thermosensitive polymers
CN103222984A (zh) * 2006-08-01 2013-07-31 普里克萨斯医药股份有限公司 泊洛沙姆用于预防和/或治疗心力衰竭的用途
WO2008033728A2 (en) 2006-09-11 2008-03-20 Pluromed, Inc. Atraumatic occlusion balloons and skirts, and methods of use thereof
US20080181952A1 (en) * 2006-12-11 2008-07-31 Pluromed, Inc. Perfusive Organ Hemostasis
KR20090114469A (ko) * 2007-02-22 2009-11-03 플루로메드, 인코포레이티드 수술후 생물학적 유체 흐름을 제어하기 위한 역 감열 폴리머의 용도
US8372387B2 (en) * 2007-04-05 2013-02-12 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
CA2695151A1 (en) * 2007-08-10 2009-02-19 Synthrx, Inc. Polymer therapy for the treatment of chronic microvascular diseases
CN101998965B (zh) 2007-11-01 2014-03-12 安斯泰来制药有限公司 免疫抑制性多肽与核酸
CN107029277A (zh) 2007-11-29 2017-08-11 健赞公司 使用纯化的逆向热敏聚合物的内镜粘膜切除
WO2009079562A2 (en) 2007-12-17 2009-06-25 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
WO2010047793A2 (en) 2008-10-21 2010-04-29 The General Hospital Corporation Cell transplantation
DE102008043343A1 (de) * 2008-10-31 2010-05-06 Evonik Goldschmidt Gmbh Silikonpolyetherblock-Copolymere mit definierter Polydispersität im Polyoxyalkylenteil und deren Verwendung als Stabilisatoren zur Herstellung von Polyurethanschäumen
WO2010072769A1 (de) 2008-12-23 2010-07-01 Basf Se Verfahren zur herstellung von polyether-blockcopolymeren
WO2011049958A2 (en) 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
GB201008902D0 (en) 2010-05-27 2010-07-14 Imp Innovations Ltd Membrane enhanced polymer sythesis
CN103153376B (zh) 2010-08-06 2018-04-20 通用医院公司以麻省总医院名义经营 用于细胞处理相关应用的系统和设备
SG190695A1 (en) 2010-11-15 2013-07-31 Mast Therapeutics Inc Methods for enhancing oxygenation of jeopardized tissue
US8975240B2 (en) 2011-03-18 2015-03-10 Baxter International Inc. Peritoneal dialysis solutions comprising glucose polymers
FR2977495B1 (fr) * 2011-07-07 2014-03-07 Sanofi Sa Composition pharmaceutique et forme galenique solide a haute teneur en dronedarone et son procede de preparation
US9662345B2 (en) 2013-06-14 2017-05-30 Professional Compounding Centers Of America Antibiotic composition for inhalation and irrigation
JP2016533377A (ja) 2013-10-16 2016-10-27 マスト セラピューティクス インコーポレイテッドＭａｓｔ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 利尿薬によって誘発される血漿量の変化
JP6202471B2 (ja) 2013-10-31 2017-09-27 日油株式会社 医用ポリオキシプロピレン重合体の製造方法および医用ポリオキシプロピレン／ポリオキシエチレンブロック共重合体の製造方法
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
AU2015287993B2 (en) 2014-07-07 2020-10-29 Liferaft Biosciences, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
WO2016007562A1 (en) * 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Methods and compositions for improving hemostasis
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
US20180353875A1 (en) * 2015-12-22 2018-12-13 Basf Se A process for purification of polyether block copolymers
EP3580261A1 (en) * 2017-02-09 2019-12-18 Basf Se A process for purification of polyether block copolymers
KR102544922B1 (ko) * 2017-12-21 2023-06-16 시그마-알드리치 컴퍼니., 엘엘씨 폴록사머 조성물 및 이의 제조 및 사용 방법
JP2020063244A (ja) 2018-10-15 2020-04-23 アヴェント インコーポレイテッド 神経アブレーションのための組成物、システム、キット及び方法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2979528A (en) * 1953-10-19 1961-04-11 Wyandotte Chemicals Corp Nitrogen-containing polyoxyalkylene detergent compositions
US2674619A (en) * 1953-10-19 1954-04-06 Wyandotte Chemicals Corp Polyoxyalkylene compounds
US3022335A (en) * 1955-03-30 1962-02-20 Wyandotte Chemicals Corp Surface active polyoxyalkylene compounds having a plurality of heteric polyoxypropylene-polyoxyethylene chains
US2854378A (en) * 1955-12-08 1958-09-30 Bristol Lab Inc Tetracycline suppository
US3036118A (en) * 1957-09-11 1962-05-22 Wyandotte Chemicals Corp Mixtures of novel conjugated polyoxyethylene-polyoxypropylene compounds
US3089818A (en) * 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
US3228834A (en) * 1962-06-08 1966-01-11 Hoffmann La Roche Pharmaceutical diluent compositions
US3140232A (en) * 1962-12-19 1964-07-07 Pfizer & Co C Color stabilization of tetracycline compositions with polypropylene glycols
US3391196A (en) * 1965-08-16 1968-07-02 Wyandotte Chemicals Corp High equivalent weight hydroxy-terminated ethylene oxide-butylene oxide polyether polyols
US3740421A (en) * 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US3450502A (en) * 1967-09-25 1969-06-17 Wyandotte Chemicals Corp Method of operating heart-lung apparatus
US3641240A (en) * 1968-09-27 1972-02-08 Wyandotte Chemicals Corp Method for the treatment of an embolus or thrombus
US3867533A (en) * 1968-12-20 1975-02-18 Basf Wyandotte Corp Preparation of aqueous gel compositions containing a water-insoluble organic ingredient
US3577522A (en) * 1969-10-10 1971-05-04 Wyandotte Chemicals Corp Methods for the treatment of shock with ethylene oxide-polypropylene glycol condensates as blood plasma substitutes
US3590125A (en) * 1969-10-10 1971-06-29 Wyandotte Chemicals Corp Physiological salt solutions of ethylene oxide-polypropylene glycol condensation products as blood plasma substitutes
US3980772A (en) * 1969-12-02 1976-09-14 Baxter Laboratories, Inc. Methods of dissolving blood clots and the like with streptokinase chemically bonded to a carbohydrate matrix
CA959759A (en) * 1970-01-15 1974-12-24 John J. Miskel Method for absorption of drugs
US3867521A (en) * 1970-08-26 1975-02-18 Scherer Corp R P Method for absorption of drugs
US4073886A (en) * 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US3956259A (en) * 1973-01-30 1976-05-11 Baxter Laboratories, Inc. Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3997458A (en) * 1974-04-12 1976-12-14 Deknatel, Incorporated Method of cleansing contaminated wounds and surgical scrub solutions for same
US4104455A (en) * 1975-03-25 1978-08-01 Toyo Soda Manufacturing Co., Ltd. Polymerization of monomer
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4195167A (en) * 1976-05-28 1980-03-25 Union Carbide Corporation Gradient polymers of two or more cyclic, organic, ring-opening, addition polymerizable monomers and methods for making same
JPS545094A (en) 1977-06-09 1979-01-16 Tokyo Tanabe Co Production of pharmaceutical urokinase from contamination free human urine
DE2732929A1 (de) * 1977-07-21 1979-02-01 Bayer Ag Polyaether, verfahren zu ihrer herstellung sowie ihre verwendung als lipidabsorptionshemmer
DE2961374D1 (en) * 1978-01-27 1982-01-28 Bp Chem Int Ltd A method for increasing the selectivity to acetic acid in the production of a mixture of c1 to c3 monocarboxylic acids by oxidation of paraffinic hydrocarbons
DE2808865A1 (de) * 1978-03-02 1979-09-13 Hoechst Ag Mikrobiozide mittel auf der basis von alkyl-di-guanidinium-salzen
US4275244A (en) 1978-05-11 1981-06-23 Basf Wyandotte Corporation Linear polyalkylene ether glycols of high molecular weight
JPS5533194A (en) 1978-08-07 1980-03-08 Scholz D Thomas Stringgfastener device including tremolant
US4305922A (en) * 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4186253A (en) * 1978-10-10 1980-01-29 The Green Cross Corporation Perfusate for preserving organ to be transplanted and preserving method
DE2850058A1 (de) * 1978-11-18 1980-05-29 Bayer Ag Polyaether-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2454409A1 (fr) * 1979-04-18 1980-11-14 Sovam Vehicule tracteur notamment pour avions gros porteurs
US4409209A (en) * 1979-10-12 1983-10-11 Ciba-Geigy Corporation Novel phosphorylmuramyl peptides and processes for the manufacture thereof
FI803077A (fi) * 1979-10-12 1981-04-13 Ciba Geigy Ag Foerfarande foer framstaellning av myramylpeptider
US4410660A (en) * 1980-05-05 1983-10-18 Montefiore Medical Center Binding assay for the detection of mycobacteria
US4489158A (en) * 1980-05-05 1984-12-18 Montefiore Hospital And Medical Center, Inc. Binding assay for the detection of mycobacteria
US4575484A (en) * 1980-05-05 1986-03-11 Montefiore Medical Center, Inc. Binding assay for the detection of mycobacteria
JPS578223A (en) * 1980-06-19 1982-01-16 Mitsui Petrochem Ind Ltd Production of alkylene oxide block copolymer
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4376118A (en) * 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
GR78246B (no) * 1981-01-23 1984-09-26 Ciba Geigy Ag
US4395393A (en) * 1981-08-10 1983-07-26 Basf Wyandotte Corporation Artificial blood emulsifiers
US4407790A (en) * 1981-09-25 1983-10-04 Economics Laboratory, Inc. Method of controlling bloat using nonionic surfactants
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
DE3234084A1 (de) * 1982-09-14 1984-03-15 B. Braun Melsungen Ag, 3508 Melsungen Pharmazeutische zubereitungen zur behandlung von unerwuenschten verwachsungen sowie deren verwendung
SU1183112A1 (ru) * 1983-08-04 1985-10-07 Научно-Исследовательский Институт Экспериментальной И Клинической Терапии Министерства Здравоохранения Гсср Способ лечени острой ишемии миокарда
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4600652A (en) * 1985-04-01 1986-07-15 Warner-Lambert Company Permanently bonded antithrombogenic polyurethane surface
US5183687A (en) * 1985-06-18 1993-02-02 Emory University Method of treating poultry for coccidiosis
US5114708A (en) * 1985-06-18 1992-05-19 Emory University Method for stimulating growth in animals
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US5250294A (en) * 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US5089260A (en) * 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US4873083A (en) * 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US5198211A (en) * 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US5032394A (en) * 1986-05-15 1991-07-16 Emory University Method of treating burns
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5078995A (en) * 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US4801452A (en) * 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US5064643A (en) * 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US4997644A (en) * 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
AU599392B2 (en) * 1986-05-15 1990-07-19 Emory University Fibrinolytic composition
US4937070A (en) * 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US4837014A (en) * 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5017370A (en) * 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5028599A (en) * 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
WO1987006831A1 (en) * 1986-05-15 1987-11-19 Emory University Composition and method for treating a thrombus and embolus
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US5047236A (en) * 1986-05-15 1991-09-10 Emory University Method of treating stroke
JP2527942B2 (ja) * 1986-09-18 1996-08-28 ティーディーケイ株式会社 磁気記録媒体
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4764567A (en) * 1986-11-20 1988-08-16 Basf Corporation Process for the preparation of polyoxyalkylene block polyethers having enhanced properties
US5811088A (en) 1987-02-20 1998-09-22 Emory University Antiinfective compounds and methods of use
DE3875871T2 (de) * 1987-02-20 1993-04-01 Univ Emory Antiinfektioese verbindungen und verfahren zur verwendung.
JPH07109520B2 (ja) 1987-02-24 1995-11-22 株式会社リコー 電子写真用感光体
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DE4014923A1 (de) * 1990-05-10 1991-11-14 Basf Ag Verfahren zur herstellung von urethan- oder urethan- und isocyanuratgruppen enthaltenden hartschaumstoffen nach dem polyisocyanat-polyadditionsverfahren und die hierfuer geeigneten polyoxyalkylen-polyole
KR100224539B1 (ko) * 1991-03-19 1999-10-15 잭 제이 루체스 개선된 생물학적 활성을 가진 폴리옥시프로필렌/폴리옥시에틸렌 공중합체 조성물
US5294365A (en) * 1991-12-12 1994-03-15 Basf Corporation Hydroxypolyethers as low-foam surfactants
US5371253A (en) * 1993-12-14 1994-12-06 Arco Chemical Technology, L.P. Process for producing esterified alkoxylated monoglycerides and diglycerides

Also Published As

Publication number Publication date
CN1069741A (zh) 1993-03-10
US6747064B2 (en) 2004-06-08
HU9302628D0 (en) 1993-12-28
JPH06506258A (ja) 1994-07-14
CA2106474A1 (en) 1992-09-20
AU662146B2 (en) 1995-08-24
AU1773092A (en) 1992-10-21
EP0576612A1 (en) 1994-01-05
US20020183398A1 (en) 2002-12-05
GR3032726T3 (en) 2000-06-30
CZ194693A3 (en) 1994-03-16
IE920860A1 (en) 1992-09-23
ATE187154T1 (de) 1999-12-15
IL101305A0 (en) 1992-11-15
US5990241A (en) 1999-11-23
ES2140408T3 (es) 2000-03-01
US5523492A (en) 1996-06-04
CA2106474C (en) 2004-02-10
HUT67762A (en) 1995-04-28
DE69230372D1 (de) 2000-01-05
EP0576612B1 (en) 1999-12-01
DK0576612T3 (da) 2000-05-22
NO933337D0 (no) 1993-09-17
US5691387A (en) 1997-11-25
USRE36665E (en) 2000-04-18
WO1992016484A1 (en) 1992-10-01
EP0576612A4 (en) 1994-11-09
IL101305A (en) 1995-11-27
US6359014B1 (en) 2002-03-19
NO933337L (no) 1993-11-17
DE69230372T2 (de) 2000-06-15
KR100224539B1 (ko) 1999-10-15
SK100893A3 (en) 1994-04-06
USRE37285E1 (en) 2001-07-17
JP2647556B2 (ja) 1997-08-27

Similar Documents

Publication Publication Date Title
NO307890B1 (no) Polyoksypropylen/polyoksyetylen-kopolymerblanding, fremgangsmÕte for fremstilling derav samt medikament omfattende en kopolymerblanding
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
MX9203439A (es) Una citocina mamifera, il-11
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
DE69426334T2 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
FR2731014B1 (fr) Molecules d'adn, preparation et utilisation en therapie genique
MD1507G2 (ro) Inhibitori, compoziţie farmaceutică pe baza lor şi procedeu de inhibare a HIV proteazei
DK0611522T3 (da) Synergistiske mikrobicide sammensætninger
DE69620877D1 (de) Arzneimittelformulierungen für il-12
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
ATE214610T1 (de) Neuartige pharmazeutische verwendungen von krill- enzymen
DK0837935T3 (da) Den 3'-ikke-translaterede region af det humane prohibitin-gen
FR2702152B1 (fr) Virus recombinants et leur utilisation en thérapie génique.
FR2694296B1 (fr) Peptides inhibant l'activité des protéines ras, préparation et utilisation.
ATE170075T1 (de) Antivirales arzneimittel enthaltend prostratin
CA2094275A1 (en) Methods and compositions for the treatment of cell proliferation disorders
ES8707488A1 (es) Un metodo para preparar maleato de 2-terc-butilamino-3'-cloropropiofenona
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
RS49520B (sr) Antimikrobno aktivne smeše
GEP20012489B (en) Use of Natural Human α-Interferon
IT1247528B (it) Composto ad attivita' terapeutica,sua preparazione e composizioni farmaceutiche che lo contengono
IT1237084B (it) Sensibilizzazione di composti metallorganici per la polimerizzazione radicalica fotocatalizzata e stabilizzazione dei preparati.
RU93056161A (ru) Блок-сополимер полиоксипропилена и полиоксиэтилена, поверхностно-активный сополимер, способ получения нетоксичного поверхностно-активного сополимера, лекарственное средство
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
FR2663327B1 (fr) Nouveaux derives de diamino-2,4 triazine-1,3,5 et leur utilisation pour le traitement et la prevention de la chute des cheveux.